These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 11340355)

  • 1. Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease.
    Nakamura T; Ushiyama C; Takahashi Y; Tanaka A; Shimada N; Ebihara I; Koide H
    Nephron; 2001 May; 88(1):80-2. PubMed ID: 11340355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Yamada S; Ueda Y; Koide H
    Am J Med Sci; 2012 Jan; 343(1):46-51. PubMed ID: 21760473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy.
    Nakamura T; Ushiyama C; Shimada N; Sekizuka K; Ebihara I; Hara M; Koide H
    Diabetes Care; 2000 Aug; 23(8):1168-71. PubMed ID: 10937516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effect of the anti-platelet drug, dilazep dihydrochloride, in patients at the microalbuminuric stage of diabetic nephropathy--a multi-center study.
    Koide H; Totsuka Y; Sugisaki T; Kitajima T; Ohmori Y; Kuriyama S; Oi K; Isogai S; Ohi H; Tomino Y
    Nihon Jinzo Gakkai Shi; 1995 Nov; 37(11):644-8. PubMed ID: 8583701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride.
    Nakamura T; Kawagoe Y; Matsuda T; Ueda Y; Ebihara I; Koide H
    Diabetes Metab Res Rev; 2005; 21(1):39-43. PubMed ID: 15386824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
    Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
    Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination AST-120 and dilazep dihydrochloride therapy reduced urinary protein excretion and serum creatinine levels in patients with chronic renal failure.
    Nakamura T; Hirokawa K; Matsuda T; Osada S; Takahashi Y; Shimada N; Koide H
    Ren Fail; 2002 Sep; 24(5):683-5. PubMed ID: 12380917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials.
    Xue C; Zhou C; Dai B; Yu S; Xu C; Mao Z; Ye C; Chen D; Zhao X; Wu J; Chen W; Mei C
    Oncotarget; 2015 Dec; 6(40):42515-29. PubMed ID: 26636542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.
    Cadnapaphornchai MA; George DM; McFann K; Wang W; Gitomer B; Strain JD; Schrier RW
    Clin J Am Soc Nephrol; 2014 May; 9(5):889-96. PubMed ID: 24721893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease.
    Sharp C; Johnson A; Gabow P
    J Am Soc Nephrol; 1998 Oct; 9(10):1908-14. PubMed ID: 9773792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients.
    Nakamura T; Ushiyama C; Osada S; Ugai K; Takahashi Y; Tanaka A; Shimada N; Ebihara I; Koide H
    Kidney Blood Press Res; 2002; 25(1):50-4. PubMed ID: 11834877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease.
    Casal JA; Hermida J; Lens XM; Tutor JC
    Kidney Int; 2005 Sep; 68(3):948-54. PubMed ID: 16105025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
    Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microalbuminuria in normotensive patients with autosomal-dominant polycystic kidney disease.
    Martinez-Vea A; Gutierrez C; Bardají A; Pastor R; García C; Peralta C; Richart C; Oliver JA
    Scand J Urol Nephrol; 1998 Sep; 32(5):356-9. PubMed ID: 9825400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of imidapril hydrochloride compared with dilazep hydrochloride administration on blood pressure and renal function in patients with chronic glomerulonephritis.
    Satonaka H; Suzuki E; Hayakawa H; Nishimatsu H; Nagata D; Oba S; Kamijo A; Takeda R; Takahashi M; Yamamoto Y; Kimura K; Hirata Y
    Int Heart J; 2005 Jul; 46(4):701-10. PubMed ID: 16157961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
    Nakagawa N; Fujino T; Kabara M; Matsuki M; Chinda J; Kikuchi K; Hasebe N;
    Hypertens Res; 2011 Oct; 34(10):1121-6. PubMed ID: 21796123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.